{"product_id":"pt-141-spray","title":"PT-141 Spray 10ml (50mg)","description":"\u003cdiv class=\"strapi-description text-sm text-[#4B5563] md:text-base line-clamp-6\"\u003e\n\u003cp\u003ePT-141 research kit. Includes a lyophilized peptide vial and accessory components for laboratory research preparation.\u003c\/p\u003e\n\u003cp\u003ePurity-tested per lot. Intended for compound characterization, reference experiments, or laboratory training applications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor laboratory research use only. Not for human or veterinary use.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv class=\"container px-3\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Characteristics\" id=\"characteristics\"\u003eCharacteristics\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolecular Formula\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eC50H68N14O10\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eCAS\tNumber\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e189691-06-3\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eMolar Mass\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003e1025.2 g\/mol\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eAmino Acid Sequence\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSynonyms\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eBremelanotide, PT-141, PT141, PT 141\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eSolubility\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWater-soluble\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eOrganoleptic Profile\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eWhite to off-white powder\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cp\u003eComposition\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cp\u003eLyophilized powder\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"How does PT-141 work?\" id=\"how-does-pt-141-work\"\u003eHow does PT-141 work?\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003ePT-141 primarily acts as a melanocortin receptor agonist, with highest affinity for the melanocortin 4 receptor (MC4R) and melanocortin 1 receptor (MC1R). Research suggests the following mechanisms:\u003c\/p\u003e\n\u003cp\u003e1. Central Nervous System: PT-141 activates MC4R in specific brain regions, particularly the hypothalamus and brainstem areas involved in sexual response. This activation is thought to influence neural pathways related to sexual desire and arousal.\u003c\/p\u003e\n\u003cp\u003e2. Neurotransmitter Modulation: Studies indicate that PT-141 may increase dopamine release in the medial preoptic area, a region crucial for sexual motivation.\u003c\/p\u003e\n\u003cp\u003e3. Peripheral Effects: PT-141's interaction with MC1R on melanocytes has been studied for potential effects on skin pigmentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Research\" id=\"research\"\u003eResearch\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003e1. HSDD in Premenopausal Women:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMultiple Phase III clinical trials have evaluated PT-141's efficacy for HSDD.\u003c\/li\u003e\n\u003cli\u003eStudies typically measured changes in sexual desire and related distress using validated scales like the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Desire\/Arousal\/Orgasm (FSDS-DAO).\u003c\/li\u003e\n\u003cli\u003eResearch has examined various dosing regimens and administration methods.including protocols evaluating PT 141 nasal spray dosage in clinical and preclinical environments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e2. Other Areas of Investigation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMale Sexual Function: Some studies have explored potential effects on erectile function, though this is not an FDA-approved use.\u003c\/li\u003e\n\u003cli\u003eDermatology: Limited research has investigated PT-141's influence on melanogenesis and potential applications in pigmentation disorders.\u003c\/li\u003e\n\u003cli\u003eCardiovascular Effects: Studies have examined PT-141's impact on blood pressure and heart rate, primarily for safety monitoring.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStudies vary in their protocols for PT-141 nasal spray dosage, depending on administration method and experimental design.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Side Effects\" id=\"side-effects\"\u003eSide Effects\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cp\u003eNausea\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFlushing\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHeadache\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFocal hyperpigmentation, which is generally reversible upon discontinuation of the drug\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Summary\" id=\"summary\"\u003eSummary\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\u003cp\u003ePT-141 (Bremelanotide) is a synthetic peptide that has been the subject of extensive clinical research, particularly in the field of female sexual health. It is approved use for HSDD in premenopausal women represents a significant development in this therapeutic area. Ongoing studies continue to explore its mechanisms of action, potential applications, and long-term safety profile particularly regarding the potential PT-141 nasal spray benefits in neuroendocrine and sexual behavior research\u003c\/p\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"References\" id=\"references\"\u003eReferences\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003col\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15134289\/\"\u003eHedlund P. PT-141 Palatin. Curr Opin Investig Drugs. 2004.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35428435\/\"\u003eRatnasiri MDK, Senarathna KW, Somarathne GPG, Silva GLL, Perera HDSM, Jayakody HAMS. Association between Bremelanotide and Hyponatremia; A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. Curr Drug Saf. 2022.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12851303\/\"\u003eVan der Ploeg LH. Obesity: Neuropeptide targets for obesity treatment. Curr Opin Investig Drugs. 2003.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37365323\/\"\u003eKingsberg SA, Schaffir J, Hatem C, Burge R, Carey K, Jordan R, Lucas J, Kim G, Liffmann D, Green L, Portman D. Efficacy, Safety, and Pharmacokinetics of Bremelanotide Self-Administered as Once-Weekly 2.75-mg Subcutaneous Injection. J Sex Med. 2023.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14999221\/\"\u003eHadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25786343\/\"\u003eSafarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26850723\/\"\u003eKingsberg SA, Clayton AH, Pfaus JG. The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. CNS Drugs. 2015.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31476935\/\"\u003eThomas HN, Thurston RC. A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review. Maturitas. 2016.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31395204\/\"\u003eSimon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Rodenberg C, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27117968\/\"\u003ePoels S, Bloemers J, van Rooij K, Koppeschaar H, Olivier B, Tuiten A. Two novel combined drug treatments for women with hypoactive sexual desire disorder. Pharmacol Biochem Behav. 2014.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15645091\/\"\u003eDiamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24070229\/\"\u003eAltof SE, Ströberg P. The potential of bremelanotide for the treatment of hypoactive sexual desire disorder. Ther Adv Urol. 2013.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18991682\/\"\u003ePfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21303940\/\"\u003ePfaus JG. Pathways of sexual desire. J Sex Med. 2009.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23899745\/\"\u003eSafarinejad MR, Shafiei N, Safarinejad S. Evaluation of the efficacy and safety of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. 2008.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23411600\/\"\u003ePortman DJ, Edelson J, Jordan R, Clayton A, Krychman ML, Kingsberg SA. Bremelanotide for hypoactive sexual desire disorder: analyses from a phase 2B dose-ranging study. J Women's Health. 2014.\u003c\/a\u003e\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c!--$!--\u003e\u003ctemplate data-dgst=\"BAILOUT_TO_CLIENT_SIDE_RENDERING\"\u003e\u003c\/template\u003e\n  \u003cdiv data-scroll-name=\"Certificate of Analysis (COA)\" class=\"\"\u003e\n  \u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n    \u003ch2 class=\"mb-6 text-2xl font-semibold leading-[2.25rem] tracking-tight md:my-0\" id=\"certificates\"\u003e\n      Certificate of Analysis (COA)\n    \u003c\/h2\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"flex w-full flex-row flex-wrap gap-x-0 gap-y-4 md:gap-x-8\"\u003e\n  \n    \u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n      \u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\t\t\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/PT-141_Spray_10ml_50mg.avif?v=1779876535\" target=\"_blank\"\u003e\n        \u003cimg alt=\"Certificate\" loading=\"lazy\" width=\"175\" height=\"227\" decoding=\"async\" data-nimg=\"1\" class=\"h-full w-full max-w-[150px] cursor-pointer rounded-none object-cover md:max-w-[175px]\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/PT-141_Spray_10ml_50mg.avif?v=1779876535\" style=\"color: transparent;\"\u003e\n\t\t\u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n  \u003c!--\/$--\u003e\u003cdiv data-scroll-name=\"Resource\" class=\"\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" id=\"resources\"\u003eResource\u003c\/h2\u003e\u003c\/div\u003e\n\u003cdiv class=\"w-full\"\u003e\u003cdiv class=\"text-base text-[#4B5563]\"\u003e\u003cspan\u003eAll products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease. Power Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Power Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act. All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. Power Peptides Products are intended strictly for research purposes only. These products are not approved by the U.S. Food and Drug Administration (FDA) for human consumption or medical use. Under no circumstances should these peptides be used for any purpose other than research. By purchasing or using our peptides, you acknowledge and agree that you will use them solely in accordance with applicable laws and regulations and that you accept full responsibility for their use. Statements made on this website have not been evaluated by the USA Food and Drug Administration.\u003c\/span\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"50mg\/10ml","offer_id":53240041799980,"sku":"PEP-SPR-PT141-50MG417965","price":143.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0971\/5731\/6908\/files\/pt-141-spray-10ml-1735841354751.png?v=1779696834","url":"https:\/\/www.powerpieeptidesus.com\/products\/pt-141-spray","provider":"Power Peptides","version":"1.0","type":"link"}